The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

EastGroup Properties, Inc.  (the "Company", "we", "our", "us" or "EastGroup") announced today its recent business activity. As ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Opdivo (nivolumab) plus Yervoy (ipilimumab) be approved as a first-line treatment for adults with unresectable or ...

The firm is updating its model after the company’s FY24 results and FY25 guidance as the company management anticipates ongoing topline growth from Jaypirca, Ebglyss, Omvoh and Kisunla and ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.

The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing authorisation for a subcutaneous (SC) formulation of Rybrevant for treating non-small cell lung cancer ...